Multiple sclerosis (MS) is a chronic, inflammatory and neurodegenerative disease affecting the central nervous system (CNS), often leading to the accumulation of irreversible clinical disability. Among the developed therapies, anti-CD20 monoclonal antibodies mediating B-cell depletion, have received increasing attention. The demonstration of the strong efficacy and good safety profile of these selective B-cell-depleting therapies has significantly contributed treat MS patients.
B-cell lineage, main anti-CD20 monoclonal antibodies and their targeted CD20 epitopes.
ACROBiosystems has developed different types of CD20 proteins include unconjugated protein, biotinylated proteins with DDM, Nanodisc and VLP, which are suitable for immunization, ELISA, SPR, BLI and FACS.
Antibody Binding Verification Data
MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with an affinity constant of 6.21 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (QC tested).
Loaded Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) on SA Biosensor, can bind Ofatumumab (Human IgG1) with an affinity constant of 0.277 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
